Evolution of the gynecologic oncology group protocols in the treatment of epithelial ovarian cancer

Clinical Obstetrics and Gynecology

Volumn 55, Issue 1, 2012, Pages 131-135

  Seamon, Leigh G ^a   Richardson, Debra L ^b   Copeland, Larry J ^c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

clinical trials; GOG; Gynecologic Oncology Group; ovarian cancer; review

Indexed keywords

2 (2 DIMETHYLAMINOETHYL) 9 METHOXY 5 NITROPYRAZOLO[3,4,5 KL]ACRIDINE; 9 AMINOCAMPTOTHECIN; ALTRETAMINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ENZASTAURIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; INTERLEUKIN 12; LEDOXANTRONE; MELPHALAN; MIFEPRISTONE; PACLITAXEL; PHOSPHORUS 32; PLATINUM; SORAFENIB; TEMSIROLIMUS; TOPOTECAN; UNINDEXED DRUG; VALSPODAR; VORINOSTAT;

ADVANCED CANCER; ALOPECIA; ANEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; EARLY CANCER; FATIGUE; FEVER; FISTULA; FOLLOW UP; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; GYNECOLOGIC ONCOLOGY GROUP; HEARING LOSS; HISTOLOGY; HUMAN; HYPERTENSION; INFECTION; INTESTINE PERFORATION; LAPAROTOMY; LOW DRUG DOSE; METABOLIC DISORDER; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROMUSCULAR DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ORGANIZATION; OVARY CANCER; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECURRENCE FREE SURVIVAL; REVIEW; SKIN DISEASE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; LAPAROTOMY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; POLYGLUTAMIC ACID; SECOND-LOOK SURGERY;

EID: 84857596702     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e318248050d     Document Type: Review

References (79)

1. DiSaia PJ. The GOG White Paper, Revised March 2011. Available at: http://www.gog.org/TheGOGWhitePaper.pdf. Accessed September 24, 2011.
2. The Gynecologic Oncology Group: report of 35 years of excellence in clinical research. XXIV Century Press Inc; 2006.
3. Hoskins W, Copeland LJ, Mannel R. Gynecologic Oncology Group Trials in Ovarian Cancer. In: The Gynecologic Oncology Group: Report of 35 years of excellence in clinical research. XXIV Century Press Inc; 2006:12-23.
4. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. N Engl J Med. 1990;322:1021-1027.
5. Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin-a Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:4350-4355. (Pubitemid 46621811)
6. Vergote IB, Vergote-DeVos LN, Abeler VM, et al. Randomized trial comparing cisplatin with radioactive phosphorous or whole abdominal irradiation as adjuvant treatment of ovarian cancer. Cancer. 1992;1992:741-749.
7. Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized trials comparing cisplatin to no further treatment or chromic phosphate (32P). GICOG: Gruppo Interregionale Collaborativo in Ginecologia Oncolgica. Ann Oncol. 1995;6:887-893.
8. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of 3 versus 6 cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;102:432-439. (Pubitemid 44353663)
9. McGuire WP, Hoskins WJ, Brady MF, et al. A phase III randomized study of cyclophosphamide and cisplatin versus paclitaxel and cisplatin in patients with suboptimal stage III and stage IV epithelial ovarian cancer. N Engl J Med. 1996; 334:1-6. (Pubitemid 26012496)
10. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200. (Pubitemid 46606249)
11. Chan JK, Tian C, Monk BJ, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer. 2008; 2202-2210. (Pubitemid 351628630)
12. Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:301-306.
13. Chan JK, Tian C, Teoh D, et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:307-311.
14. Mannel RS, Brady MF, Kohn EC, et al. A randomized phase III trial of IV carboplatin and paclitaxel 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with earlystage ovarian carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2011;122:89-94.
15. Brady LW, Blessing JA, Slayton RE, et al. Radiotherapy, chemotherapy, and combined therapy in stage III epithelial ovarian cancer. Cancer Clin Trials. 1979;2: 111-120. (Pubitemid 10040494)
16. Gall S, Bundy B, Beecham J, et al. Therapy of stage III (optimal) epithelial carcinoma of the ovary with melphalan or melphalan plus Corynebacterium parvum: a GOG study. Gynecol Oncol. 1986;25:26-30.
17. Omura GA, Bundy BN, Berek JS, et al. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a GOG study. J Clin Oncol. 1989;7:457-465. (Pubitemid 19098140)
18. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996;335:1950-1955. (Pubitemid 26428219)
19. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:1001-1007. (Pubitemid 32176274)
20. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354: 34-43. (Pubitemid 43048949)
21. Sutton GP, Bundy BN, Omura GA, et al. Stage III ovarian tumor of low malignant potential treated with ciplatin combination therapy: a GOG study. Gynecol Oncol. 1991;41:230-233.
22. Ovarian Cancer Meta-analysis Project- Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol. 1991;9: 1668-1674.
23. Hoskins WJ, Bundy BN, Thigpen JT, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small volume stage III epithelial ovarian cancer: a GOG study. Gynecol Oncol. 1992;47:159-166. (Pubitemid 23001322)
24. Bookman MA, McGuire WP, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol. 1996;14:1895-1902. (Pubitemid 26185464)
25. Eisenhauer EA, Huinink WW, Swenerton KD, et al. Euopean-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus lowdose and long versus short infusion. J Clin Oncol. 1994;12:2654-2656.
26. Tian C, Markman M, Zaino R, et al. CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithleial ovarian cancer. Cancer. 2009; 115:1395-1403.
27. Farley JH, Tian C, Rose GS, et al. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of the Gynecologic Oncology Group trials. Cancer. 2009;115:4210-4217.
28. Havrilesky L, Alvarez-Secord A, Darcy KM, et al. Cost-effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimallyresected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2008;26:4144-4150.
29. Wright JD, Tian C, Mutch D, et al. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:353-358.
30. Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group (GOG) study. J Clin Oncol. 2007; 25:3621-3627. (Pubitemid 47372600)
31. Hess LM, Barakat R, Tian C, et al. Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncolgy Group study. Gynecol Oncol. 2007;107:260-265. (Pubitemid 47575723)
32. Greer BE, Bundy BN, Ozols RF, et al. Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;99:71-79. (Pubitemid 41354585)
33. Darcy KM, Tian C, Reed E. A Gynecologic Oncology Group study of platinum- DNA adducts and excision repair cross complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res. 2007;67:4474-4481. (Pubitemid 46815098)
34. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol. 2009;27:1419-1425.
35. Howell SB, Zimm S, Markman M et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol. 1987;5:1607-1612. (Pubitemid 18010139)
36. Kirmani S, Lucas WE, Kim S, et al. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J Clin Oncol. 1991;9:649-657.
37. Wenzel LB, Huang HQ, Armstrong DK, et al. Health-related qualtiy of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Onoclogy Group study. J Clin Oncol. 2007;25:437-443. (Pubitemid 350002993)
38. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331-1338.
39. Varia MA, Stehman FB, BundyBN, et al. Intraperitoneal radioactive phosphorous (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:2849-2855. (Pubitemid 46621832)
40. Park RC, Blom J, DiSaia PJ, et al. Treatment of women with disseminated or recurrent advanced ovarian cancer with melphalan alone in combination with 5- fluorouracil and dactinomycin, or with the combination of cytoxan, 5-fluorouracil and dactinomycin. Cancer. 1980;45: 2529-2542. (Pubitemid 10105306)
41. Omura GA, Morrow CP, Blessing JA, et al. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. Cancer. 1983;51:783-789. (Pubitemid 13143151)
42. Omura G, Blessing JA, Ehrlich CE et al. A randomized trial of cyclophosphamide and doxorubicin with or without cipslatin in advanced ovarian carcinoma: a GOG study. Cancer. 1986;57: 1725-1730. (Pubitemid 16111979)
43. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995;13:1589-1599.
44. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2000;18:106-115. (Pubitemid 30036343)
45. Spriggs DR, Brady MF, Vaccarello L, et al. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:4466-4471. (Pubitemid 350013853)
46. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-2483.
47. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with supoptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994; 170:974-980. (Pubitemid 24157907)
48. Rose PG, Nerenstone S, Brady MF, et al. Secondary surgical cytoreduction for advanced ovarian cancer. N Engl J Med. 2004;351:2489-2497.
49. van der Burg MEL, van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 1995;332: 629-634.
50. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of Bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:5165-5171. (Pubitemid 350237599)
51. Hurteau JA, Blessing JA, DeCesare SL, et al. Recombinant human interleukin-12 (rhIL-12) in patients with recurrent and refractory ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2001;82:7-10. (Pubitemid 32634946)
52. Schilder R, Sill M, Chen X, et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. Clin Cancer Res. 2005;11:5539-5548. (Pubitemid 41060831)
53. Schilder RJ, Sill MW, Lee RB, et al. A phase II evaluation of imatinib methylate (IND#61135, NSC#716051) in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2008;26:3418-3425.
54. Matei D, Sill MW, Lankes HA, et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. J Clin Oncol. 2011;29:69-75.
55. Markman M, Blessing JA, DeGeest K, Lack of efficacy of 24-hour infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group trial. Gynecol Oncol.1999;75:444-446.
56. Modesitt SC, Sill M, Hoffman JS, et al. A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;109:182-186.
57. Behbakht K, Sill MW, Darcy KM, et al. Phase II of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells in persistent or recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2011;123:19-26.
58. Usha L, Sill MW, Darcy KM, et al. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011;121: 455-461.
59. Rocereto TF, Brady WE, Shahin MS, et al. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:332-334.
60. Chan JK, Penson R. A randomized phase III trial of every-3-weeks paclitaxel versus dose dense weekly paclitaxel in combination with carboplatin with or without concurrent and consolidation bevacizumab in the treatment of primary stage II, III, or IV epithelial ovarian, peritoneal, or fallopian tube cancer.Available for GOG members at: https://gogmember.gog.org/documents/ protocols/pdf/0262.pdf. Accessed July 13, 2011.
61. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel- based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21: 2460-2465. (Pubitemid 46606325)
62. Markman M, Liu PY, Moon J, et al. Impact of survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Followup of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009;114:195-198.
63. Markman M, Liu PY, Rothenberg ML, et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol. 2006;24:1454-1458. (Pubitemid 46622013)
64. Sabbatini P, Aghajanian C, Dizon D, et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. JClin Oncol. 2004;22:4523-4531. (Pubitemid 41185119)
65. Manetta A, Blessing JA, Hurteau JA. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 1998;68:45-46. (Pubitemid 28109822)
66. Markman M, Blessing JA, Moore D, et al. Altretamine (Hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 1998;69:226-229. (Pubitemid 28289964)
67. Plaxe SC, Blessing JA, Morgan MA, et al. A phase II trial of pyrazoloacridine (PZA) in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. Am J Clin Oncol. 2002;25: 45-47. (Pubitemid 34131028)
68. Hoffman MA, Blessing JA, Morgan M. Phase II trial of CI-958 in recurrent, platinum-refractory ovarian carcinoma: Gynecologic Oncology Group study. Gynecol Oncol. 2000;79:463-465.
69. Miller DS, Blessing JA,Waggoner S, et al. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;96: 67-71. (Pubitemid 39612419)
70. Rose P, Blessing J, Ball H, et al.Aphase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88:130-135. (Pubitemid 36263370)
71. Fracasso PM, Blessing J,Morgan M, et al. Phase II study of oxaliplatin in platinum resistant and refractory ovarian cancer: a Gynecologic Oncology Group study. J ClinOncol. 2003;21:2856-2859. (Pubitemid 46621833)
72. Brewer C, Blessing J, Nagourney R, et al. Cisplatin plus gemcitabine in platinumrefractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006; 103:446-450. (Pubitemid 44602150)
73. DeGeest K, Blessing JA, Morris R, et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum and taxane-resistant ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2010;28:149-153.
74. Markman M, Blessing J, Rubin S, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:436-440. (Pubitemid 43729968)
75. Miller DS, Blessing JA, Krasner C, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27:2686-2691.
76. Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;2011:111-115.
77. Sabbatini P, Sill MW, O'Malley D, et al. Aphase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study. Gynecol Oncol. 2008;111:445-460.
78. Kavanagh JJ, Sill MW,Ramirez PT, et al. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2008;18: 460-466.
79. Monk BJ, Sill MW, Hanjani P, et al. Docetaxel plus trabectedin appears active in recurrent or persistent ovarian and primary peritoneal cancer after up to three prior regimens: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2011;120:459-463.